Compare BRCB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BRCB | TECX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.9M | 393.0M |
| IPO Year | N/A | N/A |
| Metric | BRCB | TECX |
|---|---|---|
| Price | $16.61 | $35.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $28.00 | ★ $80.40 |
| AVG Volume (30 Days) | ★ 628.4K | 523.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.59 | N/A |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $13.70 |
| 52 Week High | $30.40 | $28.98 |
| Indicator | BRCB | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 82.47 |
| Support Level | $13.53 | $16.83 |
| Resistance Level | $24.71 | N/A |
| Average True Range (ATR) | 1.19 | 2.37 |
| MACD | 0.67 | 1.06 |
| Stochastic Oscillator | 84.95 | 97.81 |
Black Rock Coffee Bar Inc is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. It offers a broad range of premium coffee beverages, from its deliciously refreshing Nitro Cold Brew to its unapologetically indulgent Caramel Blondie. The company also offer competitively priced, premium classics, including the Americano and customizable Lattes, providing a high perceived value offering to its guests.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.